| Company
name |
Johnson & Johnson |
|
|
|
|
| Compare |
2013 Q1 March |
|
|
|
|
|
|
| Fiscal
Year End |
December |
|
|
|
|
|
|
| Exchange |
NYSE |
|
|
|
|
|
|
| Exchange
code |
JNJ |
|
|
|
|
www.laurison.com |
| Sector |
Healthcare |
|
|
|
|
|
|
| Industry |
Biotechnology and
Drugs |
|
|
|
|
|
|
| Description |
Johnson
& Johnson is a holding company. The Company is engaged in the research
and development, manufacture and sale of a broad range of products in the
health care field. The business of Johnson & Johnson is conducted by more
than 275 operating companies located in 60 countries, including the United
States, which sell products in virtually all countries throughout the world.
The Company’s primary focus has been on products related to human health and
well-being. The Company is organized into three business segments: Consumer,
Pharmaceutical and Medical Devices and Diagnostics. The Company's
subsidiaries operate 146 manufacturing facilities occupying approximately
21.6 million square feet of floor space. In March 2013, Johnson &
Johnson's Cordis Corporation announced the acquisition Of Flexible Stenting
Solutions, Inc.
|
|
|
|
|
|
|
All indicators in
Comparable values |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Comparative indicators |
2013 Q1 |
2012 Q1 |
Change % |
Points |
|
Comparative indicators |
2013 Q1 |
2012 Q4 |
Change % |
Points |
| Total Revenue |
17,505.00 |
16,139.00 |
8.46% |
3 |
|
Total Revenue |
17,505.00 |
17,558.00 |
-0.30% |
2 |
| Gross Profit |
11,951.00 |
11,224.00 |
6.48% |
3 |
|
Gross Profit |
11,951.00 |
11,555.00 |
3.43% |
3 |
| Operating
Income |
4,261.00 |
5,045.00 |
-15.54% |
2 |
|
Operating Income |
4,261.00 |
3,100.00 |
37.45% |
4 |
| Net Income |
3,497.00 |
3,910.00 |
-10.56% |
2 |
|
Net Income |
3,497.00 |
2,567.00 |
36.23% |
4 |
| Earnings Per
Share (EPS) |
1.22 |
1.41 |
-13.48% |
2 |
|
Earnings Per Share (EPS) |
1.22 |
0.91 |
34.07% |
4 |
| Return On
Assets (ROA) |
2.88% |
3.37% |
-14.49% |
2 |
|
Return On Assets (ROA) |
2.88% |
2.12% |
36.02% |
4 |
| Gross Margin % |
68.27% |
69.55% |
-1.83% |
2 |
|
Gross Margin % |
68.27% |
65.81% |
3.74% |
3 |
| Operating
Margin % |
24.34% |
31.26% |
-22.13% |
2 |
|
Operating Margin % |
24.34% |
17.66% |
37.87% |
4 |
| Profit Margin
% |
19.98% |
24.23% |
-17.54% |
2 |
|
Profit Margin % |
19.98% |
14.62% |
36.64% |
4 |
| Cash and Short
Term Investments |
21,668.00 |
33,847.00 |
-35.98% |
2 |
|
Cash and Short Term Investments |
21,668.00 |
21,089.00 |
2.75% |
3 |
| Total
Liabilities / Total assets % |
44.99% |
47.19% |
-4.65% |
4 |
|
Total Liabilities / Total assets % |
44.99% |
46.58% |
-3.41% |
4 |
| Total Assets /
Shares Outstanding |
43.45 |
42.32 |
2.66% |
3 |
|
Total Assets / Shares Outstanding |
43.45 |
43.79 |
-0.77% |
2 |
| Stock Price in
Exchange |
81.53 |
65.96 |
23.61% |
5 |
|
Stock Price in Exchange |
81.53 |
70.10 |
16.31% |
5 |
| Line 13 /
Line12 % |
187.63% |
155.84% |
20.40% |
3 |
|
Line 13 / Line12 % |
187.63% |
160.09% |
17.21% |
3 |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
Total |
37 |
|
|
|
|
Total |
49 |
| |
|
|
|
|
|
|
|
|
|
|
| Total Assets |
121,536.00 |
116,194.00 |
4.60% |
|
|
Total Assets |
121,536.00 |
121,347.00 |
0.16% |
|
| Total Liabilities |
54,681.00 |
54,828.00 |
-0.27% |
|
|
Total
Liabilities |
54,681.00 |
56,521.00 |
-3.26% |
|
| Shares Outstanding |
2,797.00 |
2,745.30 |
1.88% |
|
|
Shares Outstanding |
2,797.00 |
2,771.20 |
0.93% |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
LAURISON RANK |
|
3.07 |
|
|
|
|
| |
|
|
|
RECOMMENDATION |
|
BUY/HOLD |
|
|
|
|
| |
|
|
|
TARGET PRICE |
|
83.47 $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
©2013
www.laurison.com All rights reserved |
|
|
|